Autoantibodies neutralizing thrombopoietin in a patient with a megakaryocytic thrombocytopenic purpura-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Autoantibodies neutralizing thrombopoietin in a patient with a megakaryocytic thrombocytopenic purpura

Published:2000-03-15 Issue:6 Volume:95 Page:2187-2188
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kuwaki Tomoaki¹,Hagiwara Tetsuya¹,Kato Takashi¹,Miyazaki Hiroshi¹

Affiliation:

1. Pharmaceutical Research Laboratory Kirin Brewery Co., Ltd. Takasaki Gunma, Japan

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/95/6/2187/1662737/2187.pdf

Reference8 articles.

1. Korn, D 1962. Congenital hypoplastic thrombocytopenia. Am J Clin Pathol.37:405-413

2. Hoffman, R 1991. Acquired pure amegakaryocytic thrombocytopenic purpura. Semin Hematol.28:303-312

3. Kaushansky, K 1995. Thrombopoietin: the primary regulator of platelet production. Blood.86:419-431

4. Casadevall, N, Dupuy, E, Molho-Sabatier, P, Tobelem, G, Varet, B, and Mayeux, P 1996. Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med.334:630-633

5. Hill, W, and Landgraf, R 1985. Successful treatment of amegakaryocytic thrombocytopenic purpura with cyclosporine. N Engl J Med.312:1060-1061

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitor-related acquired amegakaryocytosis thrombocytopenia: a case report and literature review;Frontiers in Oncology;2024-03-07

2. Alterations in Blood Components;Reference Module in Biomedical Sciences;2024

3. Characteristics, management and outcome of acquired amegakaryocytic thrombocytopenia;British Journal of Haematology;2022-05-10

4. Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia;Frontiers in Pharmacology;2022-01-27

5. Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report;Thoracic Cancer;2021-08-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3